Clinical Phase I/IIA Study of Subcutaneous Administration of Ofatumumab in Rheumatoid Arthritis Patients on Stable Dose Methotrexate.

Trial Profile

Clinical Phase I/IIA Study of Subcutaneous Administration of Ofatumumab in Rheumatoid Arthritis Patients on Stable Dose Methotrexate.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Ofatumumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Jun 2013 Results published in The Journal of Rheumatology.
    • 24 Mar 2012 This trial has been recruiting in France and Spain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top